News

Back

MMS Positioned for Growth: New Hires Bolster Clinical Affairs

Wilmington, MA April 11, 2018—Micro Medical Solutions (MMS) is positioning itself for growth and product commercialization with the recent addition of two new employees to its organization: Amanda Panos as Vice President, Clinical Affairs, and Sarrah Val as Director of Clinical Affairs.

Ms. Panos brings 20 years of experience in the medical device industry, where her primary focus has been research of vascular disease management. She has implemented pre-clinical, first-in-man, feasibility, pivotal and post-market clinical studies in the U.S. and abroad to support market filings—experience she will draw on in her capacity at MMS.

“I’m excited to have Amanda lead our clinical efforts, as this is the foundation for building the value of MMS,” says Gregory Sullivan, CEO of MMS. “Her global experience in the execution of clinical trials will play a key role in our success moving forward. She is an outstanding addition to our leadership team,” he says.

MMS is also pleased to welcome Sarrah Val as Director of Clinical Affairs, a role that will draw on her background in clinical trial protocol development and execution.

“Sarrah is an exceptional addition to our clinical team,” Panos says. “Her proven track record of clinical achievement in the below-the-knee space is invaluable. She will be instrumental in moving MMS through critical clinical timelines. I’m honored to have her on my team,” she says.

MMS has invested significant resources in moving its clinical objectives forward, with continued focus on the company’s mission to reduce preventable amputations by improving outcomes for patients with peripheral artery disease (PAD) and critical limb ischemia (CLI). One key result is FDA approval of a feasibility study for MicroStent, which MMS is confident will lead to a pivotal IDE study, another step toward its ultimate goal of device approval.

CONTACT: Peg Thornton, Director of Corporate and Market Development, Micro Medical Solutions 732-616-9123

About CLI

Peripheral artery disease (PAD) and critical limb ischemia (CLI) affected 215 million people worldwide in 2015, predicted to be 230 million by 2020.1 CLI currently afflicts 2.8 to 3.5 million of those with PAD and is projected to rise to 4.5 to 5.6 million.2 Rates of amputations in the general population with PAD are declining, but amputations in CLI continue to escalate. It has been estimated that 25% of CLI patients will undergo major amputation. Prognosis with respect to limb preservation in CLI patients is poor, particularly in no-option CLI patients, where six-month major amputation rates have been reported to be as high as 50%.3 If something doesn’t change, the number of amputations due to CLI could exceed one million by 2030.

References: 1. Global Peripheral Artery Disease Market: Trends & Opportunities (2015-2020), February 2016 (Page 19). Daedal Research Group. 2. Critical Limb Ischemia. Volume 1 United States Epidemiology, 2010. Accessed at http://thesagegroup.us/pages/rep[orts/cliepiusreprot.php., October 14, 2016. 3. Teraa M, Conte MS, Moll FL, Verhaar MC. Contemporary Reviews: Critical Limb Ischemia: Current Trends and Future Directions. J Am Heart Assoc 2016; 5: e002938.

Back To Top